Novo Nordisk AS (NONOF)
115.70
-0.56
(-0.48%)
USD |
OTCM |
Oct 17, 15:56
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 514.93B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 16.36% |
Valuation | |
PE Ratio | 39.70 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 13.83 |
Price to Book Value | 31.88 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 0.5165 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.5071 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 24.80% |
Profile
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
URL | https://www.novonordisk.com |
Investor Relations URL | https://www.novonordisk.com/investors.html |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Large Cap/Growth |
Next Earnings Release | N/A |
Last Earnings Release | Aug. 07, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Aug. 15, 2024 |
Ratings
Profile
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
URL | https://www.novonordisk.com |
Investor Relations URL | https://www.novonordisk.com/investors.html |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Large Cap/Growth |
Next Earnings Release | N/A |
Last Earnings Release | Aug. 07, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Aug. 15, 2024 |